- PR Newswire•19 days agoMEDIA ADVISORY - Oncolytics Biotech® Inc. Announces Participation in the Canaccord Genuity 36th Annual Growth Conference
CALGARY, Aug. 10, 2016 /PRNewswire/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (ONC.TO) (ONCYF) (ONY.F), will present at the 36th Annual Canaccord Genuity Growth Conference in a session on Thursday, August 11th, 2016 at 11:00 a.m. ET. The conference takes place on August 10th and 11th in Boston, MA. Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
- CNW Group•19 days agoMEDIA ADVISORY - Oncolytics Biotech® Inc. Announces Participation in the Canaccord Genuity 36th Annual Growth Conference
MEDIA ADVISORY - Oncolytics Biotech® Inc. Announces Participation in the Canaccord Genuity 36th Annual Growth Conference
- PR Newswire•20 days agoOncolytics Biotech® Inc. Reports Additional Data from Randomized Phase II Study of REOLYSIN® in Non-Small Cell Lung Cancer
CALGARY, Aug. 10, 2016 /PRNewswire/ -- Oncolytics Biotech Inc. ( "Oncolytics" or the "Company" ) (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) today announced additional data from IND 211, a ...
Oncolytics Biotech Inc. (ONC.TO)
Toronto - Toronto Delayed Price. Currency in CAD
|Day's Range||0.31 - 0.34|
|52wk Range||0.31 - 0.90|
|1y Target Est||N/A|
|P/E Ratio (ttm)||-3.12|
|Avg Vol (3m)||89,114|
|Dividend & Yield||N/A (N/A)|